Guggenheim Initiates Coverage On Retension Pharmaceuticals with Buy Rating, Announces Price Target of $55

Benzinga · 1d ago
Guggenheim analyst Seamus Fernandez initiates coverage on Retension Pharmaceuticals (NASDAQ:RTSN) with a Buy rating and announces Price Target of $55.